Biorelevant subcutaneous in vitro test predicts the release of human and fast acting insulin formulations.
Schöner TA, Vogel V, Venczel M, Knoth K, Kamm W, Paehler T, Louit G, Terán IT, Mundinger P, Marker A, Loos P, Hittinger M, Lehr CM.
Schöner TA, et al. Among authors: kamm w.
Int J Pharm. 2024 Apr 25;655:123995. doi: 10.1016/j.ijpharm.2024.123995. Epub 2024 Mar 14.
Int J Pharm. 2024.
PMID: 38490402